Novartis touts longer-lasting AMD rival to Eylea

05:27 EST 13 Nov 2017 | Pharmafile

Novartis posted strong results for its wet age-related macular degeneration (AMD) drug, by showing superiority against Eylea in Phase 3 trials. The data sets Novartis up to take a chunk of the nearly $5 billion that Eylea and Lucentis, the leading products in the market, reap annually.

The main selling point that Novartis’ drug, RTH258 (brolucizumab), has over competitors is that it only needs to be delivered to patients once every 12-weeks, a four-week improvement on potential rival, Eylea.

read more

Original Article: Novartis touts longer-lasting AMD rival to Eylea


More From BioPortfolio on "Novartis touts longer-lasting AMD rival to Eylea"

Quick Search


Relevant Topics

Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...